Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pulmonary arterial hypertension
Marketing
Merck aims to 'outnumber' pulmonary arterial hypertension
Mere weeks after earning the FDA’s signoff on new drug Winrevair to treat PAH, Merck has kicked off an educational campaign around the rare disease.
Andrea Park
Apr 16, 2024 10:37am
Courts clear FDA to approve Liquidia's PAH drug Yutrepia
Apr 2, 2024 9:33am
FDA signs off on Merck’s potential blockbuster Winrevair for PAH
Mar 26, 2024 5:11pm
FDA approves Johnson & Johnson's combo pill Opsynvi for PAH
Mar 25, 2024 11:05am
Par recalls batch of Remodulin generic over particulate concerns
Mar 13, 2024 8:15am
J&J dumps Opsumit trial upon pulmonary hypertension flop
Sep 7, 2023 11:03am